GSK Enters Strategic Alliance with Vesalius Therapeutics for Parkinson’s Disease Treatments

Strategic Alliance:
GSK has entered a multi-target strategic alliance with Vesalius Therapeutics, a company founded by Flagship Pioneering, to develop novel treatments for Parkinson's disease and another undisclosed neurodegenerative condition24.

Financial Terms:
Vesalius will receive $80 million in upfront and equity payments and is eligible for potential milestone payments of up to $570 million along with tiered royalties for the preclinical small molecule program24.

Development and Commercialization:
GSK will be responsible for advancing Vesalius' preclinical small molecule program and will control all development and commercialization efforts25.

Platform Utilization:
Vesalius will leverage its platform, which uses large-scale human genetics, genomics, stem cell studies, and artificial intelligence, to identify novel intervention points in Parkinson's disease and another neurodegenerative indication25.

Collaboration Scope:
The collaboration grants GSK worldwide development and commercial rights to the preclinical small molecule program with an initial focus in Parkinson's disease35.

Sources:

2. https://www.goodwinlaw.com/en/news-and-events/news/2024/11/announcements-lifesciences-goodwin-advises-vesalius-gsk-to-develop-treatments-for-parkinsons

3. https://firstwordpharma.com/story/5911497

4. https://www.fiercebiotech.com/biotech/gsk-inks-parkinsons-pact-flagships-vesalius-570b-biobucks

5. https://www.davispolk.com/experience/gsk-strategic-alliance-vesalius-therapeutics